ArticleJournal of gastrointestinal oncology2025
Construction and validation of a nomogram model for predicting peritoneal metastasis in gastric cancer based on ferroptosis-relate genes and clinicopathological features.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer peritoneal metastasis (GCPM) is a lethal condition. Current diagnostic methods for GCPM, such as imaging and serum tumor markers, lack specificity and sensitivity. Research suggests that utilizing gene signatures to predict GCPM shows significant predictive ability. Nonetheless, the predictability of GCPM using ferroptosis-related genes (FRGs) remains unknown. We aim to construct a nomogram based on FRGs for early diagnosis of GCPM. Methods: RNA sequencing and clinical data of patients with gastric cancer (GC) were downloaded from Gene Expression Omnibus (GEO) databases. GCPM was diagnosed through imaging, biopsy and cytology. A GCPM prediction model was developed based on six distinctively expressed FRGs, and the efficiency of the model was assessed through receiver operating characteristic (ROC) curves in both experimental and validation cohorts. Subsequently, 115 clinical samples were examined by immunohistochemistry (IHC) to validate the prediction model's accuracy. Results: Our analysis included 282 patients, among whom 54 had GCPM while 228 did not. Patients were randomly distributed into experimental and validation groups at a 3:2 ratio. Least absolute shrinkage and selection operator (LASSO) regression identified the coefficients of six FRGs, with a risk score calculated for every patient. Univariate and multivariate logistic analyses revealed that both risk score and pathological stage were significantly associated with GCPM. The area under the curve (AUC) values for the training and validating sets implied good predictability for GCPM (0.827 and 0.767, respectively). Combining the risk score with the tumor node metastasis (TNM) stage substantially improved predictability (AUCs were 0.916 and 0.848 respectively). Lastly, a nomogram incorporating the risk score and TNM stage was constructed, which shows good clinical utility through decision curve analysis (DCA). The IHC results from 115 clinical samples were consistent with these findings. Conclusions: A nomogram model based on FRGs and clinicopathological features was constructed, demonstrating impressive predictive value for GCPM. This enables timely and personalized therapeutic interventions, thereby benefiting gastric cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.